

# Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

Nicholas McGranahan and Charles Swanton\*

\*Correspondence: [charles.swanton@cancer.org.uk](mailto:charles.swanton@cancer.org.uk)

<http://dx.doi.org/10.1016/j.ccell.2015.06.007>

(Cancer Cell 27, 15–26; January 12, 2015)

Page 16 of this review contains two errors. We erroneously stated that the range of the hypermutated glioma cases was “7–450”; this should in fact read “39–249.” The correct sentence is as follows: “Costello’s laboratory performed a comparison of the genomic landscape of gliomas at initial diagnosis and recurrence and found that 6 of 10 tumors that recurred as glioblastomas, a high-grade tumor with worse prognosis, displayed evidence of hypermutation—exhibiting 39–249 times the mutational load per megabase compared with primary gliomas.”

In addition, for clarity, the legend for Figure 1B should read “low-grade glioma” and not “glioblastoma tumor.” The correct sentence is as follows: “The evolution of a low-grade glioma that has undergone treatment with Temozolomide (TMZ).”